In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allegra Authorized Generic Scripts Could Reach 40% By Year-End, Sanofi Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Teva describes the launch of its generic fexofenadine as one of the firm’s “most successful.”

You may also be interested in...



UCB’s Next Allergy Partner Is Sanofi-Aventis

Xyzal, pending in the U.S. for allergic rhinitis treatment, could be a replacement for Allegra.

UCB’s Next Allergy Partner Is Sanofi-Aventis

Xyzal, pending in the U.S. for allergic rhinitis treatment, could be a replacement for Allegra.

Teva/Barr Get The Green Light To Continue Marketing Generic Allegra

A New Jersey federal judge denied Sanofi-Aventis' request for a preliminary injunction to stop Teva/Barr from marketing generic Allegra.

Related Content

Topics

UsernamePublicRestriction

Register

PS061353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel